ACXP

Business Context and Reporting Period

Acurx Pharmaceuticals, Inc. (ACXP) is a clinical-stage biopharmaceutical company focused on developing a novel class of antibiotics targeting Gram-positive bacteria, with its lead candidate, ibezapolstat, in development for the treatment of Clostridioides difficile infections (CDI). The company is an emerging growth company and a smaller reporting company listed on the Nasdaq Capital Market.

This summary covers the quarterly period ended March 31, 2026, as reported in Form 10-Q.

Key Financial Metrics

Note: The company has not generated any revenue since inception. All financial figures are unaudited.

Material Changes vs. Prior Period

• Reduced Net Loss: Net loss decreased by approximately 22% to $1.68 million from $2.15 million in the prior year quarter, driven by lower operating expenses.
• Expense Reduction: Total operating expenses declined 21% to $1.72 million. R&D expenses dropped 43% due to reduced manufacturing costs and consulting fees compared to Phase 2b/Phase 3 preparation costs in the prior year. G&A expenses decreased 13% primarily due to lower professional and legal fees.
• Significant Equity Issuance: The company issued 1,016,119 shares of common stock under an Equity Line of Credit (ELOC) with Lincoln Park Capital Fund, LLC, raising approximately $3.1 million in net proceeds during the quarter. This contrasts with the prior year, which saw proceeds from registered direct offerings.
• Reverse Stock Split: A 1-for-20 reverse stock split was effected on August 4, 2025. All share and per-share data in this filing have been adjusted retrospectively.

Guidance, Outlook, and Risks

Management Commentary and Outlook

• Clinical Progress: The company announced a new clinical development initiative in March 2026 to expand the ibezapolstat program into recurrent CDI (rCDI), with an open-label pilot trial expected to begin enrollment in Q4 2026.
• Liquidity: As of March 31, 2026, the company held approximately $9.3 million in cash. Management states this is not sufficient to meet anticipated cash requirements for at least 12 months from the issuance date.
• Financing Needs: The company expects to continue incurring losses and will require additional equity financing or grant funding to sustain operations. There is no assurance that such funding will be available on acceptable terms.

Risks and Contingencies

• Going Concern: The company's independent auditors have expressed substantial doubt about its ability to continue as a going concern due to significant accumulated deficits and negative operating cash flows.
• Regulatory Approval: Success depends entirely on the successful development and FDA approval of ibezapolstat. Failure in clinical trials or regulatory rejection would materially harm the business.
• Dilution: Future capital raises will likely involve the issuance of additional equity, causing significant dilution to existing shareholders.
• Third-Party Dependence: The company relies on third-party manufacturers and CROs for clinical trial execution and drug manufacturing, introducing supply chain and quality control risks.

Investor Verification Checklist

• Cash Runway: Verify the specific timeline for cash depletion and the status of any new financing agreements post-March 31, 2026.
• ELOC Utilization: Confirm the remaining capacity under the $12.0 million Lincoln Park ELOC and the terms of subsequent sales (e.g., the April 2026 offering mentioned in subsequent events).
• Clinical Trial Enrollment: Monitor the progress of the new rCDI pilot trial and the timeline for the planned Phase 3 registration trial.
• Share Count: Track the rapid increase in outstanding shares (from ~1.1M in Q1 2025 to ~3.4M in Q1 2026) and its impact on per-share value.
• Accrued Liabilities: Review the $2.5 million in accounts payable and accrued expenses, specifically the $2.38 million in accrued R&D costs, to understand immediate cash obligations.